the U1 small nuclear ribonucleoprotein (70 kDa; referred to as RNP70 thereafter) and the RNA polymerase III subunit RP155. The anti-TPO Ab that had become undetectable 1 year after allo-HSCT reappeared with an increased titer 2 years after allo-HSCT. She survived without leukemia for 44 years and is currently undergoing treatment with a thyroid hormone preparation owing to subclinical hypothyroidism. Complete donor chimerism, based on amplification of short tandem repeats of peripheral blood and bone marrow, was sustained up to the final follow-up. The donor did not show any obvious signs of autoimmune disease 4 years after PBSC apheresis. Although neither ANA immunofluorescence nor anti-TPO Ab was identified, EUROLINE assay detected ANA against RP155 in the donor serum.
Auto-Abs are considered to be secreted by long-lived plasma cells (LLPCs). 6 Unlike short-lived plasma cells, LLPCs have shown to be resistant to cyclophosphamide and TBI in an NZB/W F1 mouse model, 7, 8 which demonstrated an SLE-like autoimmune disease that could be partially rescued by allo-HSCT. 9 The same may be true in humans; furthermore, study of autologous HSCT in patients with SLE has shown that ANAs persist or relapse in some patients. 10 In our patient, titers of auto-Abs decreased, with some becoming undetectable. These findings suggested that intensified myeloablative allo-HSCT may eradicate the LLPCs. Nevertheless, ANA showing a nucleolar pattern emerged 6 months after allo-HSCT. These findings raise concerns about where the auto-Abs come from. At least three classes of immune cells/responses are thought to be responsible for auto-Ab production: (1) the donorderived mature immune cells contaminating the PBSC bag, (2) patient-derived LLPCs surviving even after allo-HSCT and (3) autoreactive T and B cells differentiating from donor hematopoietic stem cells. As for the auto-Ab against RP155, donor-derived LLPCs may contribute to the auto-Ab production. This hypothesis was partially supported by the fact that donor-derived HLA Abs were produced after HSCT from HLA-Ab-positive donors, but the Ab titer kinetics between our study and Taniguchi et al. 11 was quite different; the anti-HLA Ab peaked shortly after HSCT and then gradually decreased, whereas the nucleolar pattern of ANAs in our patient emerged months after HSCT and thereafter gradually increased, which implies that different mechanisms underlie the two cases. Donor CD4 + T cells may contribute to the expansion of plasmablasts and LLPCs, as is the case with the WT1-peptide immunization model. 12 The clinical findings that anti-RP155 Abs have been observed in systemic sclerosis but not in SLE 13 also support the hypothesis that the auto-Abs were derived from donor cells and not patient cells. However, the presence of auto-Ab against RNP70 could not be explained by this hypothesis. As the auto-Ab against RNP70, which generally shows the speckled pattern, is often detected in patients with SLE, patientderived LLPCs may survive after HSCT and secrete auto-Abs with an unusual immunofluorescence pattern. Although the pathogenesis of auto-Ab against RP155 and RNP70 in our patient and donor is unknown, close follow-up should be performed because autoAbs sometimes precede autoimmune disease. 14 The changes observed for the anti-TPO Ab provide the third perspective that donor hematopoietic stem cell-derived autoreactive T and B cells may newly accumulate months after HSCT and secrete auto-Abs, which is thought to be the same mechanism as that underlying autoimmune diseases as well as cGvHD.
The risk of cancer is of increasing concern in patients with SLE. Non-Hodgkin's lymphomas are the most frequent hematological malignancies in patients with SLE, but AML is rare. 15 AML is a very rare complication in patients with APS. 16 However, it is clear that further studies on such complicated situations in clinical practice are required because the incidence of comorbidity is expected to increase based on improvements in the survival ratio of SLE as well as the increased leukemia risk in patients with SLE. The findings from the current study may provide new insights into the reconstitution pattern and temporal variation of ANAs and auto-Abs throughout allo-HSCT. Abbreviations: allo-HSCT = allogeneic-hematopoietic stem cell transplantation; ANA = antinuclear antibody; D = day; dsDNA = double-stranded DNA; Homo = homogeneous; M = month; NA = not available; Spec = speckled.
